Primary: Demonstrate reduced frequency and intensity of maladaptive behaviors as measured by
the Aberrant Behavior Checklist (ABC) Irritability subscale in subjects given Nuedexta 8
weeks over subjects given placebo.
Secondary: Demonstrate a trend towards reduced aggressive behavior as measured by Overt
Aggression Scale (OAS).